Blockade of sodium-glucose cotransporter 2 suppresses high glucose-induced angiotensinogen augmentation in renal proximal tubular cells

American Journal of Physiology - Renal Physiology

Volumn 318, Issue 1, 2020, Pages F67-F75

  Satou, Ryousuke ^a   Cypress, Michael W ^a   Cooper Woods, T ^a   Katsurada, Akemi ^a   Dugas, Courtney M ^a   Fonseca, Vivian A ^a   Gabriel Navar, L ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensinogen; Diabetes; Proximal tubular cells; Sodium glucose cotransporter 2

Indexed keywords

ANGIOTENSINOGEN; CANAGLIFLOZIN; GLUCOSE; OLMESARTAN; PLASMID DNA; PYRUVATE SODIUM; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA; SODIUM GLUCOSE COTRANSPORTER 2;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GLUCOSE LEVEL; GLUCOSE TRANSPORT; KIDNEY PROXIMAL TUBULE; MALE; MOUSE; MRNA EXPRESSION LEVEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION LEVEL; UPREGULATION; WESTERN BLOTTING; ANIMAL; CELL LINE; DRUG EFFECT; EPITHELIUM CELL; METABOLISM; PHARMACOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSINOGEN; ANIMALS; CANAGLIFLOZIN; CELL LINE; EPITHELIAL CELLS; GLUCOSE; KIDNEY TUBULES, PROXIMAL; MALE; MICE; REACTIVE OXYGEN SPECIES; RENIN-ANGIOTENSIN SYSTEM; SODIUM-GLUCOSE TRANSPORTER 2; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85076876334     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00402.2019     Document Type: Article

References (54)

1. Abdo S, Shi Y, Otoukesh A, Ghosh A, Lo CS, Chenier I, Filep JG, Ingelfinger JR, Zhang SL, Chan JS. Catalase overexpression prevents nuclear factor erythroid 2-related factor 2 stimulation of renal angiotensinogen gene expression, hypertension, and kidney injury in diabetic mice. Diabetes 63: 3483–3496, 2014. doi:10.2337/db13-1830.
2. Ansary TM, Nakano D, Nishiyama A. Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the renin-angiotensin system. Int J Mol Sci 20: 629, 2019. doi:10.3390/ijms20030629.
3. Beck RW, Riddlesworth TD, Ruedy K, Ahmann A, Haller S, Kruger D, McGill JB, Polonsky W, Price D, Aronoff S, Aronson R, Toschi E, Kollman C, Bergenstal R; DIAMOND Study Group. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med 167: 365–374, 2017. doi:10.7326/M16-2855.
4. Brady JA, Hallow KM. Model-based evaluation of proximal sodium reabsorption through SGLT2 in health and diabetes and the effect of inhibition with canagliflozin. J Clin Pharmacol 58: 377–385, 2018. doi:10.1002/jcph.1030.
5. Brezniceanu ML, Liu F, Wei CC, Tran S, Sachetelli S, Zhang SL, Guo DF, Filep JG, Ingelfinger JR, Chan JS. Catalase overexpression attenuates angiotensinogen expression and apoptosis in diabetic mice. Kidney Int 71: 912–923, 2007. doi:10.1038/sj.ki.5002188.
6. Briasoulis A, Al Dhaybi O, Bakris GL. SGLT2 inhibitors and mechanisms of hypertension. Curr Cardiol Rep 20: 1, 2018. doi:10.1007/ s11886-018-0943-5.
7. Burns KD, Cherney D. Renal angiotensinogen and sodium-glucose cotransporter-2 inhibition: insights from experimental diabetic kidney disease. Am J Nephrol 49: 328–330, 2019. doi:10.1159/000499598.
8. DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol 13: 11–26, 2017. doi:10.1038/nrneph.2016.170.
9. Engelgau MM, Narayan KM, Herman WH. Screening for type 2 diabetes. Diabetes Care 23: 1563–1580, 2000. doi:10.2337/diacare.23.10. 1563.
10. Foote C, Perkovic V, Neal B. Effects of SGLT2 inhibitors on cardiovascular outcomes. Diab Vasc Dis Res 9: 117–123, 2012. doi:10.1177/ 1479164112441190.
11. Garagliano JM, Katsurada A, Miyata K, Derbenev AV, Zsombok A, Navar LG, Satou R. Advanced glycation end products stimulate angiotensinogen production in renal proximal tubular cells. Am J Med Sci 357: 57–66, 2019. doi:10.1016/j.amjms.2018.10.008.
12. Ghezzi C, Loo DDF, Wright EM. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia 61: 2087–2097, 2018. doi:10.1007/s00125-018-4656-5.
13. Hopfer U, Jacobberger JW, Gruenert DC, Eckert RL, Jat PS, Whit-sett JA. Immortalization of epithelial cells. Am J Physiol Cell Physiol 270: C1–C11, 1996. doi:10.1152/ajpcell.1996.270.1.C1.
14. Hsieh TJ, Fustier P, Wei CC, Zhang SL, Filep JG, Tang SS, Ingelfinger JR, Fantus IG, Hamet P, Chan JS. Reactive oxygen species blockade and action of insulin on expression of angiotensinogen gene in proximal tubular cells. J Endocrinol 183: 535–550, 2004. doi:10.1677/joe. 1.05871.
15. Hung MH, Chen YL, Chen LJ, Chu PY, Hsieh FS, Tsai MH, Shih CT, Chao TI, Huang CY, Chen KF. Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced β-catenin activation. Cell Death Dis 10: 420, 2019. doi:10.1038/s41419-019-1646-6.
16. Ingelfinger JR, Zuo WM, Fon EA, Ellison KE, Dzau VJ. In situ hybridization evidence for angiotensinogen messenger RNA in the rat proximal tubule. An hypothesis for the intrarenal renin angiotensin system. J Clin Invest 85: 417–423, 1990. doi:10.1172/JCI114454.
17. Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, Perkovic V; CREDENCE study investigators. The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol 46: 462–472, 2017. doi:10.1159/000484633.
18. Kaji K, Nishimura N, Seki K, Sato S, Saikawa S, Nakanishi K, Furukawa M, Kawaratani H, Kitade M, Moriya K, Namisaki T, Yoshiji H. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. Int J Cancer 142: 1712–1722, 2018. doi:10.1002/ijc.31193.
19. Kamiyama M, Garner MK, Farragut KM, Kobori H. The establishment of a primary culture system of proximal tubule segments using specific markers from normal mouse kidneys. Int J Mol Sci 13: 5098–5111, 2012. doi:10.3390/ijms13045098.
20. Kamiyama M, Garner MK, Farragut KM, Sofue T, Hara T, Morikawa T, Konishi Y, Imanishi M, Nishiyama A, Kobori H. Detailed localization of augmented angiotensinogen mRNA and protein in proximal tubule segments of diabetic kidneys in rats and humans. Int J Biol Sci 10: 530–542, 2014. doi:10.7150/ijbs.8450.
21. Kamiyama M, Zsombok A, Kobori H. Urinary angiotensinogen as a novel early biomarker of intrarenal renin-angiotensin system activation in experimental type 1 diabetes. J Pharmacol Sci 119: 314–323, 2012. doi:10.1254/jphs.12076FP.
22. Kobori H, Ozawa Y, Satou R, Katsurada A, Miyata K, Ohashi N, Hase N, Suzaki Y, Sigmund CD, Navar LG. Kidney-specific enhancement of ANG II stimulates endogenous intrarenal angiotensinogen in gene-targeted mice. Am J Physiol Renal Physiol 293: F938–F945, 2007. doi:10.1152/ajprenal.00146.2007.
23. Liang Y, Arakawa K, Ueta K, Matsushita Y, Kuriyama C, Martin T, Du F, Liu Y, Xu J, Conway B, Conway J, Polidori D, Ways K, Demarest K. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 7: e30555, 2012. doi:10.1371/journal.pone.0030555.
24. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32: 650 –657, 2009. doi:10.2337/dc08-1863.
25. Liu J, Edgington-Giordano F, Dugas C, Abrams A, Katakam P, Satou R, Saifudeen Z. Regulation of nephron progenitor cell self-renewal by intermediary metabolism. J Am Soc Nephrol 28: 3323–3335, 2017. doi: 10.1681/ASN.2016111246.
26. Maeda S, Matsui T, Takeuchi M, Yamagishi S. Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis. Diabetes Metab Res Rev 29: 406 –412, 2013. doi:10.1002/dmrr.2407.
27. Mancini SJ, Boyd D, Katwan OJ, Strembitska A, Almabrouk TA, Kennedy S, Palmer TM, Salt IP. Canagliflozin inhibits interleukin-1βstimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms. Sci Rep 8: 5276, 2018. doi:10.1038/s41598-018-23420-4.
28. Matthews DR, Li Q, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Desai M, Hiatt WR, Nehler M, Fabbrini E, Kavalam M, Lee M, Neal B. Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. Diabetologia 62: 926–938, 2019. doi:10.1007/ s00125-019-4839-8.
29. Miyata K, Ohashi N, Suzaki Y, Katsurada A, Kobori H. Sequential activation of the reactive oxygen species/angiotensinogen/renin-angiotensin system axis in renal injury of type 2 diabetic rats. Clin Exp Pharmacol Physiol 35: 922–927, 2008. doi:10.1111/j.1440-1681.2008.04938.x.
30. Moe OW, Ujiie K, Star RA, Miller RT, Widell J, Alpern RJ, Henrich WL. Renin expression in renal proximal tubule. J Clin Invest 91: 774–779, 1993. doi:10.1172/JCI116296.
31. Navar LG, Harrison-Bernard LM, Nishiyama A, Kobori H. Regulation of intrarenal angiotensin II in hypertension. Hypertension 39: 316–322, 2002. doi:10.1161/hy0202.103821.
32. Navar LG, Prieto MC, Satou R, Kobori H. Intrarenal angiotensin II and its contribution to the genesis of chronic hypertension. Curr Opin Pharmacol 11: 180–186, 2011. doi:10.1016/j.coph.2011.01.009.
33. O’Leary R, Penrose H, Miyata K, Satou R. Macrophage-derived IL-6 contributes to ANG II-mediated angiotensinogen stimulation in renal proximal tubular cells. Am J Physiol Renal Physiol 310: F1000–F1007, 2016. doi:10.1152/ajprenal.00482.2015.
34. Ohashi N, Urushihara M, Satou R, Kobori H. Glomerular angiotensinogen is induced in mesangial cells in diabetic rats via reactive oxygen species-ERK/JNK pathways. Hypertens Res 33: 1174 –1181, 2010. doi: 10.1038/hr.2010.143.
35. Panchapakesan U, Pegg K, Gross S, Komala MG, Mudaliar H, Forbes J, Pollock C, Mather A. Effects of SGLT2 inhibition in human kidney proximal tubular cells–renoprotection in diabetic nephropathy? PLoS One 8: e54442, 2013. doi:10.1371/journal.pone.0054442.
36. Park S, Bivona BJ, Kobori H, Seth DM, Chappell MC, Lazartigues E, Harrison-Bernard LM. Major role for ACE-independent intrarenal ANG II formation in type II diabetes. Am J Physiol Renal Physiol 298: F37–F48, 2010. doi:10.1152/ajprenal.00519.2009.
37. Pohl M, Kaminski H, Castrop H, Bader M, Himmerkus N, Bleich M, Bachmann S, Theilig F. Intrarenal renin angiotensin system revisited: role of megalin-dependent endocytosis along the proximal nephron. J Biol Chem 285: 41935–41946, 2010. doi:10.1074/jbc.M110.150284.
38. Rahman A, Hitomi H, Nishiyama A. Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure. Hypertens Res 40: 535–540, 2017. doi:10.1038/ hr.2016.193.
39. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54: 3427–3434, 2005. doi:10.2337/diabetes.54.12.3427.
40. Sarnoski-Brocavich S, Hilas O. Canagliflozin (invokana), a novel oral agent for type-2 diabetes. P T 38: 656–666, 2013.
41. Satou R, Gonzalez-Villalobos RA, Miyata K, Ohashi N, Katsurada A, Navar LG, Kobori H. Costimulation with angiotensin II and interleukin 6 augments angiotensinogen expression in cultured human renal proximal tubular cells. Am J Physiol Renal Physiol 295: F283–F289, 2008. doi:10. 1152/ajprenal.00047.2008.
42. Satou R, Miyata K, Gonzalez-Villalobos RA, Ingelfinger JR, Navar LG, Kobori H. Interferon-γ biphasically regulates angiotensinogen expression via a JAK-STAT pathway and suppressor of cytokine signaling 1 (SOCS1) in renal proximal tubular cells. FASEB J 26: 1821–1830, 2012. doi:10.1096/fj.11-195198.
43. Shin SJ, Chung S, Kim SJ, Lee EM, Yoo YH, Kim JW, Ahn YB, Kim ES, Moon SD, Kim MJ, Ko SH. Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes. PLoS One 11: e0165703, 2016. doi:10.1371/ journal.pone.0165703.
44. Takeshige Y, Fujisawa Y, Rahman A, Kittikulsuth W, Nakano D, Mori H, Masaki T, Ohmori K, Kohno M, Ogata H, Nishiyama A. A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats. Hypertens Res 39: 415–422, 2016. doi:10.1038/hr.2016.2.
45. Terada Y, Tomita K, Nonoguchi H, Marumo F. PCR localization of angiotensin II receptor and angiotensinogen mRNAs in rat kidney. Kidney Int 43: 1251–1259, 1993. doi:10.1038/ki.1993.177.
46. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT, Molitch ME. Diabetic kidney disease: a report from an ADA consensus conference. Am J Kidney Dis 64: 510–533, 2014. doi:10.1053/j.ajkd.2014.08. 001.
47. van Bommel EJ, Muskiet MH, Tonneijck L, Kramer MH, Nieuwdorp M, van Raalte DH. SGLT2 inhibition in the diabetic kidney-from mechanisms to clinical outcome. Clin J Am Soc Nephrol 12: 700–710, 2017. doi:10.2215/CJN.06080616.
48. Wang L, Lei C, Zhang SL, Roberts KD, Tang SS, Ingelfinger JR, Chan JS. Synergistic effect of dexamethasone and isoproterenol on the expression of angiotensinogen in immortalized rat proximal tubular cells. Kidney Int 53: 287–295, 1998. doi:10.1046/j.1523-1755.1998.00759.x.
49. Wang XX, Levi J, Luo Y, Myakala K, Herman-Edelstein M, Qiu L, Wang D, Peng Y, Grenz A, Lucia S, Dobrinskikh E, D’Agati VD, Koepsell H, Kopp JB, Rosenberg AZ, Levi M. SGLT2 protein expression is increased in human diabetic nephropathy: SGLT2 protein inhibition decreases renal lipid accumulation, inflammation, and the development of nephropathy in diabetic mice. J Biol Chem 292: 5335–5348, 2017. doi: 10.1074/jbc.M117.779520.
50. Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol 4: 211–220, 2016. doi:10.1016/ S2213-8587(15)00417-9.
51. Woods TC, Satou R, Miyata K, Katsurada A, Dugas CM, Klingenberg NC, Fonseca VA, Navar LG. Canagliflozin prevents intrarenal angiotensinogen augmentation and mitigates kidney injury and hypertension in mouse model of type 2 diabetes mellitus. Am J Nephrol 49: 331–342, 2019. doi:10.1159/000499597.
52. Yacoub R, Campbell KN. Inhibition of RAS in diabetic nephropathy. Int J Nephrol Renovasc Dis 8: 29–40, 2015. doi:10.2147/IJNRD.S37893.
53. Yamout H, Perkovic V, Davies M, Woo V, de Zeeuw D, Mayer C, Vijapurkar U, Kline I, Usiskin K, Meininger G, Bakris G. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol 40: 64 –74, 2014. doi:10.1159/000364909.
54. Yoshimoto T, Furuki T, Kobori H, Miyakawa M, Imachi H, Murao K, Nishiyama A. Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes. J Investig Med 65: 1057–1061, 2017. doi:10.1136/jim-2017-000445.